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with a BCR-ABL positive CML in major molecular
response during dasatinib treatment unmasks an
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Friederike Pastore1,2*, Stephanie Schneider1, Oliver Christ1, Wolfgang Hiddemann1,2 and Karsten Spiekermann1,2Abstract
We present a case of a 42-year old female with the rare diagnosis of a myeloproliferative syndrome harboring both
a BCR-ABL transclocation and a JAK2V617F mutation.
Initially diagnosed with a CML, the patient underwent treatment with imatinib followed by dasatinib. Despite a
major molecular response, the patient developed a thrombocytosis. Molecular analyses revealed a heterozygous
JAK2V617F mutation, which was detected retrospectively in the bone marrow at the time of CML diagnosis.
This case underlines the complexity of MPS pathogenesis. For the clinician, a JAK2 mutational screening should be
performed in CML patients without hematological response in the absence of BCR-ABL.
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In March 2005 a 42-year old woman presented with a
leukocytosis of 350 G/l, a thrombocytosis of 498 G/l
and an elevated lactate dehydrogenase (LDH) level of
2207 U/l. The differential blood count showed 47%
neutrophils, 14% myelocytes, 11% promyelocytes, 10%
myeloblasts, 5% metamyelocytes, 5% eosinophils, 5%
basophils and 3% lymphocytes.
The diagnosis of a typical chronic myeloid leukemia
(CML) was established after detection of an aberrant
karyotype 46,XX,t(9;22)(q34;q11) in all 25 metaphases
and the presence of the BCR-ABL-rearrangement (98%)
in the bone marrow aspirate by FISH. The quantitative
BCR-ABL/ABL ratio determined by RT-PCR was 53.0.
The spleen was enlarged with 22.5 cm. The patient was
classified as low risk according to Sokal [1] and Hasford
[2] risk scores for survival.
After an initial treatment with hydroxyurea resulting
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reproduction in any medium, provided the orsyndrome therapy was changed to imatinib (400 mg/
day) in April 2005.
Under the treatment with imatinib the patient achieved a
complete hematological remission within two months. Since
cytogenetic and molecular remission was not obtained even
after one year of therapy with imatinib, a mutation analysis
of BCR-ABL was performed in October 2006, which re-
vealed no evidence for point mutations within the BCR-ABL
kinase domain. After an initial decrease, the BCR-ABL/ABL
ratio continuously increased from 3.4 to 33.3 in February
2009. The patient was recommended to increase the dose of
imatinib, which she declined.
In June 2009, the patient developed a hematological
relapse of the CML with leukocytosis (24 G/l), throm-
bocytosis (853 G/l) and elevated LDH level (290 U/l).
Interphase FISH detected 59% BCR-ABL positive cells
and the BCR-ABL/ABL ratio was markedly elevated
(48.13). Therapy was changed to a second line regimen
with dasatinib (Figure 1).
Within three months of therapy with dasatinib, a
hematological response with normalization of the white
blood count (WBC) and platelet count, as well as a
complete cytogenetic (no BCR-ABL positive nuclei inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Figure 1 Summary of blood counts, molecular analyses and cytoreductive therapy in a patient with a CML with JAK2V617F clonal
evolution under treatment with imatinib and dasatinib.
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ABL ratio dropped to 0.6) was recorded.
A major molecular response, with a normal karyotype
and a BCR-ABL/ABL ratio <0.1 (0.04) in the quantitative
RT-PCR was diagnosed in October 2010.
Until March 2013 repeated molecular and cytogenetic
analyses showed a constant complete cytogenetic and
major molecular remission.
Despite the absence of the Philadelphia chromosome, the
patient developed and retained a marked thrombocytosis
and elevated LDH levels again since February 2010.
Therefore, a JAK2-V617F mutation analysis was
performed in October 2010, which demonstrated a
heterozygous V617F [3].
The amount of the mutated JAK2-allel was quantified
with the MutaQuant™ kit from Ipsogene. Retrospective
analyses of gDNA from peripheral blood or bone mar-
row samples from the first diagnosis until June 2010 re-
vealed that the JAK2 mutant allel had already been
present in the bone marrow at first diagnosis at a very
low level (ratio JAK2V617F/JAK2wt : 0.122).
The amount of JAK2 mutant allel was constant in 2006
and showed a rapid increase in 2007 (from 1.091 in January
to 6.754 in May) under treatment with imatinib. In June
2006, when the CML relapse was diagnosed and therapy
was changed to dasatinib, the JAK2V617F/JAK2wt ratio
was 9.9 and further increased since then to 30.3 in May
2011. Thus, both, BCR-ABL and JAK2V617F coexisted
simultaneously. Whereas leucocytosis was due to genetic
abnormalities, persistant thrombocytosis was mainly caused
by the JAK2V617F.
Conclusion and discussion
We present a patient with a BCR-ABL positive CML who
achieved a major molecular response after second line
treatment with dasatinib. Occurrence of an impressive
thrombocytosis and elevated LDH levels in the absence of
BCR-ABL led to the diagnosis of an additional JAK2V617-
positive clone. Retrospectively, the JAK2V617F mutant
was already detectable at a very low level simultaneously
to BCR-ABL at first diagnosis of CML. This is a rare case
unmasking a JAK2V617F-positive clone in a patient with
a BCR-ABL positive CML.
JAK2 is a tyrosine kinase that plays an important role in
the signalling pathways of myeloid hematopoietic cells. A
single acquired activating point mutation in JAK2 (V617F)
occurs in the majority of BCR-ABL negative MPS such as
ET, PV and OMF [4-7], but is only rarely found in BCR-
ABL positive CML [8,9].
The hypothesis, that BCR-ABL and JAK2V617F are mu-
tually exclusive [8] has been disproved in the last few years.
There have been reports about patients with a previous
history of a JAK2V617F positive polycythemia vera (PV)
[10-12], ET [13] or osteomyelofibrosis (OMF) [14] thatdeveloped a BCR-ABL positive CML and other patients
that suffered a CML who developed features of a PV
[15,16], an ET [17] or an OMF [18,19].
The JAK2V617F mutation was shown to precede the ac-
quisition of BCR-ABL [10,14], co-occur with [16,19,20]
and also succeed [15,21] the BCR-ABL fusion transcript.
In the published literature data are still controversial
concerning the aspect if Philadelphia chromosome negative
MPS and CML develop as separate diseases originating
from different stem cells, or if these entities evolve from a
mutual cell of origin by the acquisition of JAK2V617F and
the BCR-ABL fusion gene at different time points.
Some authors favor the hypothesis, that a single sub-
clone of progenitor cells carrying a JAK2V617F successively
acquires the BCR-ABL translocation [10]. Those cells ac-
quire a proliferative advantage, but disappear when exposed
to imatinib. In contrast, the clone harboring JAK2V617F
only will not be sensitive to imatinib.
Other models postulate that a JAK2V617F and the
BCR-ABL fusion derive independently parallel from sus-
ceptible polyclonal stem cells [15,22-24] or might be
preceeded by another independent genetic hit (founder
mutation) which predisposes to their acquisition [18].
In our patient, at initial diagnosis a JAK2V617F was de-
tectable at a very low level whereas the BCR-ABL clone
was already 100% of the CML clone. Considering the mere
frequencies this suggests that the two mutations might have
arisen independently in different bone marrow cells.
Nevertheless, applying the hypothesis of Bocchia et al.
[10] this does not exclude the possibility that the BCR-ABL
positive clone might have represented a sub-clone of
JAK2V617F mutated cells which had gained a growth
advantage.
Under therapy with imatinib the JAK2 mutant level in-
creased suggesting a growth advantage of JAK2V617F posi-
tive/BCR-ABL negative cells in relation to JAK2V617F
positive/BCR-ABL positive cells which might have been at
least to some degree antagonized by imatinib. These observa-
tions are in line with the fact that CML therapy with imatinib
was shown to reveal Philadelphia chromosome negative
clonal disorders in more than 10% of CML patients [25].
Finally, therapy with dasatinib might have eliminated the
JAK2F617F-positive/ BCR-ABL positive clone. The suppres-
sion of the BCR-ABL clone might have facilitated growth of
the JAK2V617F-positive cells without the BCR-ABL fusion
that were unaffected by dasatinib. This theory is supported
by continuously rising levels of the JAK2V617F/JAK2wt
ratio and progressive thrombocytosis and leukocytosis in
our patient. This is in line with the so called “gene dosis
hypothesis” meaning that JAK2V617F expression level cor-
relate with the number of involved cell lines and thus the
type of disease (low level - > ET; high level - > PV) [26,27].
The increase of platelets to > 1000 G/l was followed by an
increase of leukocytes.
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carrying either JAK2V617F or BCR-ABL. Yet it does not
exclude the possibility of BCR-ABL/JAK2V617F double-
positive sub-clones.
According to our hypothesis, the BCR-ABL clone which
showed an initial clonal pre-dominance was successfully
reduced by treatment with dasatinib which unmasked
clinical features attributed to JAK2V617F-positive disease.
These results represent the complex pathogenesis of
MPS and demonstrate the possibility of overlaps or coexis-
tences between the BCR-ABL positive and negative MPS.
For the clinician, we recommend to analyze the JAK2 mu-
tation status in patients with an established diagnosis of
CML who develop myeloproliferation and/or disease pro-
gression despite molecular remission of the CML.
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